No Data
FibroGen Management to Meet Virtually With William Blair
Virtual Meeting to be held on August 26 hosted by William Blair.
Russell Investments Group Ltd. Sells 18,425 Shares of FibroGen, Inc. (NASDAQ:FGEN)
Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchang
FibroGen, Inc. (NASDAQ:FGEN) Sees Large Decline in Short Interest
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a drop of 9
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 9.2% in July
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a decrease of 9.2% from t
FibroGen (NASDAQ:FGEN) Given New $14.00 Price Target at Cowen
FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports. Several other analysts have a
Cowen Boosts FibroGen (NASDAQ:FGEN) Price Target to $14.00
FibroGen (NASDAQ:FGEN – Get Rating) had its price objective boosted by stock analysts at Cowen to $14.00 in a research report issued on Monday, Stock Target Advisor reports. Cowen's price target sug
FibroGen (NASDAQ:FGEN) Cut to "Hold" at StockNews.com
StockNews.com lowered shares of FibroGen (NASDAQ:FGEN – Get Rating) from a buy rating to a hold rating in a report issued on Wednesday morning. Separately, The Goldman Sachs Group lowered their targe
Brokers Set Expectations for FibroGen, Inc.'s Q3 2022 Earnings (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities research analysts at Jefferies Financial Group increased their Q3 2022 earnings per share estimates for shares of FibroGen in a research report
William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities researchers at William Blair increased their Q3 2022 earnings per share estimates for shares of FibroGen in a note issued to investors on Monda
FibroGen (NASDAQ:FGEN) Announces Earnings Results
FibroGen (NASDAQ:FGEN – Get Rating) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0
Loading...